Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL10036575 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL1200511 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3398599 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29355040 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL30197067 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369467-A1 | Process for the Preparation of N-Monosubstituted beta-Amino Alcohols | LONZA AG (CH) | 2017-12-28 | — | — | US | claimed |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | ALAPATI MOHAN MURALI (IN) | 2017-05-11 | — | — | US | claimed |
| US-20150361064-A1 | Process for the Preparation of N-Monosubstituted beta-Amino Alcohols | LONZA AG (CH) | 2015-12-17 | — | — | US | claimed |
| CN-104478849-A | Method for preparing noradrenaline reuptake dual inhibitor | GUANGDONG HEC PHARMACEUTICAL | 2015-04-01 | — | — | CN | claimed |
| US-8957227-B2 | Preparation of Duloxetine® hydrochloride using optically active methylhydroxylaminopropanol compound as an intermediate | SCI PHARMTECH, INC. (TW) | 2015-02-17 | — | — | US | claimed |
| CN-104163811-A | New method for preparation of duloxetine hydrochloride | CHONGQING SHENGHUAXI PHARMA CO | 2014-11-26 | — | — | CN | claimed |
| EP-2386549-B1 | Process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by using an optically active methylhydroxylaminopropanol compound as intermediate | SCI PHARMATECH INC (TW) | 2014-03-19 | — | — | EP | claimed |
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | SCI PHARMTECH, INC. (TW) | 2014-01-02 | — | — | US | claimed |
| US-8614336-B2 | Process for preparing N-methyl-N-hydroxyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine derivative | SCI PHARMTECH, INC. (TW) | 2013-12-24 | — | — | US | claimed |
| EP-2125772-B1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT (HU) | 2013-09-11 | — | — | EP | claimed |
| EP-1476439-A1 | PREPARATION OF N-METHYL-3-HYDROXY- 3-(2-THIENYL)PROPYLAMINE VIA NOVEL THIOPHENE DERIVATIVES CONTAINING CARBAMATE GROUPS AS INTERMEDIATES | Degussa AG (DE) | 2004-11-17 | — | — | EP | claimed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| WO-2004065376-A1 | 3-METHYLAMINO-1-(2-THIENYL)-1-PROPANONE, PRODUCTION AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-05 | — | — | WO | claimed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| WO-2003070720-A1 | PREPARATION OF N-METHYL-3-HYDROXY- 3-(2-THIENYL)PROPYLAMINE VIA NOVEL THIOPHENE DERIVATIVES CONTAINING CARBAMATE GROUPS AS INTERMEDIATES | DEGUSSA AG (DE) | 2003-08-28 | — | — | WO | claimed |
| EP-0457559-A2 | Chiral synthesis of 1-aryl-3-aminopropan-1-ols | ELI LILLY AND COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | claimed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | claimed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | ADRA1A, ADRA2A, ADRB1 | SLC6A4 96/4885SLC6A2 120/4885SLC6A3 168/4885 |
| US-20150361064-A1 | Process for the Preparation of N-Monosubstituted beta-Amino Alcohols | ADH1A, ADH1C, ASNS | SLC6A4 1609/4885SLC6A2 736/4885SLC6A3 1292/4885 |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SLC5A1, SLC6A4, SLC6A2 | SLC6A4 2/4885SLC6A2 3/4885SLC6A3 5/4885 |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | SLC6A4 1298/4885SLC6A2 1405/4885SLC6A3 874/4885 |
| US-20170369467-A1 | Process for the Preparation of N-Monosubstituted beta-Amino Alcohols | ADH1A, ADH1C, ASNS | SLC6A4 1609/4885SLC6A2 736/4885SLC6A3 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.